Aim. CRBN is the most widely used E3 ligase for PROTACs development due to the large variety of its glutarimide ligands, which have good drug-like properties and low molecular weight. However, because of the racemization and low stability of glutarimides, the process of drug development faces many challenges [1-2]. This work aims to study and analyze the set of more stable phenyl dihydrouracil molecules as promising binders for CRBN. These investigations will be helpful during the development of PROTACs. Conclusions. The IC₅₀ value of tested phenyl dihydrouracil Compound 1 is similar to the well-known Cereblonglutarimide ligand pomalidomide, which indicates that phenyl dihydrouracils might be a good replacement for the Thalidomide derivatives with the potential to be used during CRBN-based PROTACs development.